Introduction {#Sec1}
============

DNA supercoiling plays a critical role in several crucial DNA transactions including DNA replication, recombination, transcription, and DNA repair^[@CR1],[@CR2]^. In bacteria, DNA molecules are usually (−) supercoiled^[@CR3]^. DNA supercoiling *in vivo* is determined by counteractions of DNA topoisomerase I & IV (relaxation) and DNA gyrase ((−) supercoiling)^[@CR4],[@CR5]^. Inhibition of DNA gyrase activities by gyrase inhibitors causes the relaxation of the DNA templates or accumulation of (+) supercoiled plasmids^[@CR6]^ and also induces the expression of DNA gyrase in bacteria^[@CR7]^. Deletion of *topA* from the chromosome results in the production of hypernegatively supercoiled DNA molecules at the exponential phase of bacteria^[@CR8]^. Recent genomic studies also showed that DNA supercoiling is critical for transcription regulation of many genes during bacterial cell growth^[@CR9]--[@CR13]^.

Transcription can also disrupt localized DNA supercoiling *in vitro*^[@CR14]--[@CR18]^ and *in vivo*^[@CR6],[@CR8],[@CR19]--[@CR23]^. Liu and Wang formulated a twin supercoiled domain model of transcription to explain how transcription affects localized DNA supercoiling^[@CR24]^. As the length of the RNA transcript increases, it becomes more and more difficult for the RNA-RNA polymerase complex to rotate around the DNA molecule. At a turning point, energetically, it is more practical to rotate the DNA about its own helical axis. Further translocation of the RNA-RNA polymerase along the DNA template generates a positively supercoiled domain in front of the transcribing RNA polymerase and a negatively supercoiled domain behind it^[@CR24]^. Many *in vitro* and *in vivo* results support this twin supercoiled domain model. For instance, in defined protein systems, transcription is able to drive close circular DNA templates to hypernegatively supercoiled status in the presence of DNA gyrase because DNA gyrase converts a fraction of the transient (+) supercoils into permanent (−) supercoils^[@CR14]--[@CR18]^. Likewise, in *E. coli topA* strains, transcription at the exponential phase is able to drive close circular DNA templates to hypernegatively supercoiled because DNA gyrase converts (+) supercoiled domain into (−) supercoils^[@CR6],[@CR8],[@CR19]--[@CR23]^.

Transcription-coupled DNA supercoiling (TCDS) is also able to activate supercoiling-sensitive promoters in bacteria^[@CR25]--[@CR29]^. The best-studied case is the activation of bacterial Leu-500 promoter (P~leu-500~) by TCDS, a promoter containing a single A-to-G mutation in the promoter region of the *leu* operon^[@CR30],[@CR31]^. Previous studies demonstrated that transcription-driven localized supercoiling rather than global supercoiling density was responsible for the activation of P~leu-500~^[@CR25]--[@CR27],[@CR32]--[@CR37]^. The orientation of TCDS had opposite effects where (−) supercoiling domain activated P~leu-500~ and (+) supercoiling domain suppressed the promoter^[@CR27]^. In our previously published studies^[@CR38]^, using uniquely designed linear plasmids, we demonstrated that transient and localized (−) DNA supercoiling can strongly activate P~leu-500~. The activation of P~leu-500~ is dependent of the promoter strength and the length of RNA transcripts, unique properties of TCDS as predicted by the twin-supercoiled domain mechanism. We also demonstrated that TCDS could be generated on topologically open DNA molecules *in E. coli* cells. These results suggest that topological boundaries or barriers are not necessary for the generation of TCDS *in vivo*.

The *E. coli gyrA* promoter (P~gyrA~) is another supercoiling sensitive promoter and stimulated by relaxation of DNA templates^[@CR7],[@CR39],[@CR40]^. Early mutation studies showed that the stimulation of P~gyrA~ stems from a 20 bp DNA sequence around the −10 region of P~gyrA~^[@CR39],[@CR40]^. Since this 20 bp DNA sequence is intrinsically bent or curved^[@CR41]^, it is possible that the DNA bend or curvature functions as a supercoiling sensor for the activation by DNA relaxation^[@CR41]^. Nevertheless, whether P~gyrA~ can be inhibited by TCDS has not been examined. Here, using different DNA templates including the *E. coli* chromosome, we show that transient and localized (−) TCDS is able to strongly inhibit P~gyrA~ in *E. coli*. We also found that fluoroquinolones, such as ciprofloxacin, were able to substantially increase the expression of the firefly luciferase controlled by P~gyrA~ coupled to a divergent IPTG-inducible promoter in the presence of IPTG. This unique property of TCDS may be used to screen and identify antimicrobial compounds targeting bacterial DNA gyrase.

Results and Discussion {#Sec2}
======================

In our previous studies^[@CR38]^, using an *in vivo* system that contains *E. coli topA* strain *VS111(DE3)ΔlacZ* or wild-type strain *MG1655(DE3)ΔlacZ* and a circular or linear plasmid DNA template, we demonstrated that transient and localized TCDS from a divergently-coupled transcription unit potently activated the supercoiling-sensitive promoter P~leu-500~. In this study, we decided to utilize this system to examine whether and how TCDS inhibits a different supercoiling-sensitive promoter P~gyrA~. For this purpose, we substituted P~leu-500~ with P~gyrA~ divergently coupled to the strong IPTG-inducible promoter P~T7A1/O4~ (Fig. [1](#Fig1){ref-type="fig"}). The distance between these two promoters is 92 bp (Fig. [1A](#Fig1){ref-type="fig"}). As shown in Fig. [1C,D](#Fig1){ref-type="fig"}, we used 2 sets of 4 Rho-independent, *rrnB T1* transcription terminators to block transcription from P~T7A1/O4~ and P~gyrA~, respectively. In this case, transcription is restricted to a selected region of the plasmids^[@CR22]^. Circular plasmid pZXD144 and linear plasmid pZXD150 were used to transform *VS111(DE3)ΔlacZ* or *MG1655(DE3)ΔlacZ*. After IPTG was added to *E. coli* cells in the early log phase, luciferase activities were used to monitor the inhibition of P~gyrA~. Results in Fig. [2](#Fig2){ref-type="fig"} show that TCDS strongly inhibits the supercoiling-sensitive P~gyrA~ for both circular and linear plasmids. For example, TCDS from *E. coli* RNA polymerase on pZXD144 inhibited 53% and 68% of P~gyrA~ in *VS111(DE3)ΔlacZ* and *MG1655(DE3)ΔlacZ*, respectively, comparing with the activities of P~gyrA~ in the absence of IPTG (Fig. [2B](#Fig2){ref-type="fig"}). TCDS on pZXD150 inhibited 42% and 63% of P~gyrA~ in *VS111(DE3)ΔlacZ* and *MG1655(DE3)ΔlacZ*, respectively (Fig. [2D](#Fig2){ref-type="fig"}). Due to the fact that linear DNA templates cannot be permanently supercoiled^[@CR42]^, these results unambiguously demonstrated that transient and localized TCDS, rather than global supercoiling, inhibits the divergently coupled P~gyrA~. Interestingly, for circular plasmid pZXD144, the expression level of β-galactosidase is always higher in *MG1655(DE3)ΔlacZ* than that in *VS111(DE3)ΔlacZ* in the absence or presence of IPTG (Fig. [2A](#Fig2){ref-type="fig"}), which is consistent with our previously published results^[@CR43]^. In contrast, for linear plasmid pZXD150, the expression level of β-galactosidase is lower in *MG1655(DE3)ΔlacZ* comparing with that in *VS111(DE3)ΔlacZ* (Fig. [2C](#Fig2){ref-type="fig"}). These results suggest that DNA supercoiling plays some roles in regulating the activities of P~T7A1/O4~^[@CR38]^. Please note that each *E. coli* cell carries approximate 1 copy of a linear plasmid, the overall expression levels of firefly luciferase are much lower for linear plasmids^[@CR38]^. Since the *topA* strain *VS111* is a DNA topoisomerase I deletion strain, it should have greater supercoiling fluctuations when disturbed by TCDS. As a result, P~gyrA~ should be more sensitive to TCDS. Indeed, our results showed that P~gyrA~ is more sensitive to the IPTG concentration, indicating that it is more sensitive to TCDS (Fig. [2B and D](#Fig2){ref-type="fig"}).Figure 1Experimental design of a pair of divergently coupled transcription units to examine transcription inhibition of P~gyrA~ by TCDS *in vivo*. (**A**) Divergently coupled promoters P~T7A1/O4~ and P~gyrA~, respectively, control the expression of β-galactosidase (*lacZ*) and firefly luciferase (*luc*). (**B**) The DNA sequence of the pair of divergently coupled promoters, P~T7A1/O4~ and P~gyrA~. Underlined are P~gyrA~ and P~T7A1/O4~ with −10 and −35 regions. (**C**,**D**) Maps of circular plasmid pZXD144 and linear plasmid pZXD150. Winged triangles represent Rho-independent *rrnB* T1 transcription terminators.Figure 2Inhibition of P~gyrA~ by TCDS for circular plasmid pZXD144 (**A**,**B**) and linear plasmid pZXD150 (**C,** **D**). The activities of β-galactosidase (Miller's units) and firefly luciferase (RLU, relative light units) were determined as described under Methods and plotted versus the IPTG concentration. (**A**,**B**) *E. coli* strains *MG1655(DE3)ΔlacZ* (black squares and lines) and *VS111(DE3)ΔlacZ* (red circles and lines) carrying pZXD144 were used. (**C**,**D**) *E. coli* strains *MG1655(DE3)ΔlacZ* (black squares and lines) and *VS111(DE3)ΔlacZ* (red circles and lines) carrying pZXD150 were used. The standard deviation (SD) was determined according to results from three independent experiments.

Next, we examined how TCDS inhibits P~gyrA~ on the *E. coli* chromosome. First, we placed a \~5 kb DNA fragment carrying the divergently coupled P~gyrA~ and P~T7A1/O4~ promoters (Fig. [1A](#Fig1){ref-type="fig"}) into the *attTn7* site of the *E. coli* chromosome (Fig. [S1](#MOESM1){ref-type="media"}; the 84.2 min of the *E. coli* chromosome^[@CR44]^) using a procedure of transposon Tn7^[@CR45]^ to yield a wild type strain *FL1181* (*MG1655(DE3)ΔlacZ attTn7::P*~*T7A1/O4*~*lacZ-P*~*gyrA*~*luc*) and a *topA* strain *FL1182* (*VS111(DE3)ΔlacZ attTn7::P*~*T7A1/O4*~*lacZ-P*~*gyrA*~*luc*). Due to technical difficulties, the four T1 transcription terminators were not included in these constructs. Similar to results for plasmid DNA templates as shown above, transcription by *E. coli* RNA polymerase can substantially inhibit transcription from P~gyrA~ on the *E. coli* chromosome (Fig. [3A,B](#Fig3){ref-type="fig"}). For example, TCDS was able to inhibit 24% and 47% of P~gyrA~ in *FL1181* and *FL1182*, respectively. Interestingly, in the absence of IPTG, P~gyrA~ in *FL1182* is more active than that in *FL1181* (Fig. [3B](#Fig3){ref-type="fig"}). As demonstrated previously^[@CR43]^, in the absence of IPTG, P~T7A1/O4~ is much more active in the wildtype strain *MG1655* that that in the *topA* strain *VS111*. Although the DNA templates may be more negatively supercoiled globally in *VS111*, the localized supercoiling around P~gyrA~ in the wildtype strain *MG1655* should be more negatively supercoiled than that in *VS111* due to TCDS. In this way, the expression level of luciferase in *VS111* should be higher than that in *MG1655* in the absence of IPTG.Figure 3Strong inhibition of the supercoiling-sensitive P~gyrA~ by TCDS on the chromosome. (**A**,**B**) TCDS assays for P~gyrA~ on the chromosome. *E. coli* strains *FL1181* (*MG1655(DE3)ΔlacZ attTn7::P*~*T7A1/O4*~*lacZ-P*~*gyrA*~*luc*; black squares and lines) and *FL1182* (*VS111(DE3)ΔlacZ attTn7::P*~*T7A1/O4*~*lacZ-P*~*gyrA*~*luc*; red circles and lines) were used. The activities of β-galactosidase and firefly luciferase were determined as described under Methods and plotted versus the IPTG concentration. (**C**,**D**) Effects of novobiocin (**C**) and ciprofloxacin (**D**) on P~gyrA~ of *FL1181* (black squares and lines) and *FL1182* (red circles and lines) in the absence of IPTG. (**E**,**F**) DNA gyrase inhibitors significantly enhanced the expression of firefly luciferase for *FL1181* and *FL1182* in the presence of IPTG. Overnight cell cultures were diluted 100-fold and grown until OD600 reached \~0.2. Then 0.5 mM of IPTG and various concentrations of ciprofloxacin or other antibiotics were added to the cell cultures. After 30 min incubation, the activities of β-galactosidase and firefly luciferase were determined described under Methods. (**C**) Ciprofloxacin (CIXP) inhibited the expression of β-galactosidase. (**D**) CIXP greatly enhanced the expression of firefly luciferase. The standard deviation (SD) was determined according to results from three independent experiments.

Since it was shown that gyrase inhibitors, such as coumermycin, quinolones, and novobiocin, are able to induce the expression of gyrA and gyrB in bacteria^[@CR46],[@CR47]^, we also treated *FL1181* and *FL1182* with two gyrase inhibitors, novobiocin and ciprofloxacin, and examined whether these two gyrase inhibitors are able to increase the firefly luciferase expression under the control of P~gyrA~. At the early exponential stage, novobiocin slightly enhanced the expression of firefly luciferase in *FL1181* (Fig. [3C](#Fig3){ref-type="fig"}) and did not have much effect on the expression of firefly luciferase in the *topA* strain *FL1182* (Fig. [3C](#Fig3){ref-type="fig"}). Ciprofloxacin at low concentrations slightly stimulated the expression of firefly luciferase for both strains (Fig. [3D](#Fig3){ref-type="fig"}; the differences appear to be statistically insignificant) and inhibited the expression of firefly luciferase in *FL1181* at 50 μM (Fig. [3D](#Fig3){ref-type="fig"}). Intriguingly, in the presence of IPTG, the stimulation of firefly luciferase expression by ciprofloxacin was significantly amplified (Fig. [3F](#Fig3){ref-type="fig"}) although ciprofloxacin at high concentrations completely inhibited the expression of β-galactosidase for both strains (Fig. [3E](#Fig3){ref-type="fig"}). We noticed some differences between these two *E. coli* strains. For the wild type strain *FL1181*, the stimulation of firefly luciferase expression by ciprofloxacin decreased at higher concentrations, i.e., 20 and 50 μM. For *topA* strain *FL1182*, however, the stimulation by ciprofloxacin plateaued at 10 μM and stayed high at 50 μM. These results suggest that topoisomerase I plays a role in the regulation of P~gyrA~ activities in *E. coli*. We further tested several other gyrase inhibitors including levofloxacin, norfloxacin, enrofloxacin, and novobiocin, and found that only fluoroquinolones dramatically stimulated the expression of firefly luciferase in *FL1181* and *FL1182* in the presence of IPTG (Fig. [4A and C](#Fig4){ref-type="fig"}). Novobiocin's effect on the expression of firefly luciferase is negligible for both strains (Fig. [4A and C](#Fig4){ref-type="fig"}). At the tested concentrations, i.e., 5 and 10 µM, these fluoroquinolones slightly inhibit the growth of the two *E. coli* strains (Fig. [S2](#MOESM1){ref-type="media"}). We also tested several other types of antibiotics, such as transcription inhibitors (rifampicin), protein synthesis inhibitors (kanamycin and tetracycline), and cell wall synthesis inhibitors (ampicillin), and found that all these antibiotics inhibited the expression of firefly luciferase in *FL1181* and *FL1182* (Figs [4B,D](#Fig4){ref-type="fig"} and [S3](#MOESM1){ref-type="media"}). These results suggest that the enhancement of the expression of firefly luciferase is specific for gyrase inhibitors, especially for fluoroquinolones. These results also suggest that this stimulation assay can be used to identify antibiotics targeting bacterial DNA gyrase.Figure 4The stimulation of expression of firefly luciferase of *FL1181* (**A**) and *FL1182* (**C**) by fluoroquinolones in the presence of 0.5 mM IPTG. CIXP, LVF, EFX, NFX, and novobiocin represent ciprofloxacin, levofloxacin, enrofloxacin, norfloxacin, and novobiocin, respectively. Three bars from left to right represent luciferase activities in the presence of 0, 5, and 10 μM of fluoroquinolones, respectively. (**B** and **D**) The inhibition of expression of firefly luciferase by other antibiotics (none gyrase inhibitors) for *FL1181* (**B**) and *FL1182* (**D**). RMP, KM, AMP, and TC represent rifampicin, kanamycin, ampicillin, and tetracycline, respectively. The following are concentrations used in the experiments from left to right: AMP, 0, 150, 300 μM; KM, 0, 40, 80 μM; RMP, 0, 25, 50 μM; TC, 0, 10, 20 μM. The standard deviation (SD) was determined according to results from three independent experiments.

We believe that the twin supercoiled domain model of transcription^[@CR24]^ can explain why gyrase inhibitors are able to stimulate the expression of firefly luciferase in *FL1181* and *FL1182*. At the early exponential phase, RNA polymerase is actively transcribing genes along the *E. coli* chromosome, introducing localized DNA supercoiling around these genes, and remodeling the chromosome. For *FL1181* and *FL1182*, the divergently coupled P~gyrA~ and P~T7A1/O4~ promoters with the *luc* and *lacZ* genes are located at 84.2 min of the *E. coli* chromosome near the seven rRNA operons^[@CR48]^. Since the *E. coli* RNA polymerase transcribes along these seven rRNA operons away from 84.2 min of the *E. coli* chromosome, transcription should introduce significant amounts of (−) supercoils to this region. As a result, P~gyrA~ is repressed. For the wild type strain *FL1181*, in the presence of novobiocin, DNA gyrase is no longer capable of removing (+) supercoiled domain generated during transcription. Topoisomerase I, on the other hand, relaxes (−) supercoiled domain. In this way, DNA templates including the chromosome should be more relaxed, which resulted in the stimulation of the expression of firefly luciferase under the control of P~gyrA~ (Fig. [3C](#Fig3){ref-type="fig"}). Since the *topA* strain *FL1182* does not have DNA topoisomerase I to remove (−) supercoiled domain, the DNA supercoiling status in *FL1182* will not fluctuate significantly in the presence of novobiocin. This is the reason why novobiocin did not greatly affect the expression of firefly luciferase in *FL1182* (Fig. [3C](#Fig3){ref-type="fig"}). Ciprofloxacin is a different DNA gyrase inhibitor and forms gyrase-cipro-DNA complexes that cause the termination of transcription for both *FL1181* and *FL1182* (Fig. [3E](#Fig3){ref-type="fig"}). The (−) supercoiled domain should not be formed. As a result, ciprofloxacin was able to "stimulate" the expression of firefly luciferase for both strains (Fig. [3D](#Fig3){ref-type="fig"}).

Regarding why fluoroquinolones, in the presence of IPTG, are able to enhance the expression of firefly luciferase (Fig. [4A and C](#Fig4){ref-type="fig"}), we favor the model depicted in Fig. [5](#Fig5){ref-type="fig"} for explanation. In the presence of IPTG, transcription initiated from the strong P~T7A1/O4~ produces a significant amount of (−) supercoils behind the RNA polymerase and as a result inhibits the expression of firefly luciferase by P~gyrA~ (Fig. [3B](#Fig3){ref-type="fig"}). However, ciprofloxacin stabilizes gyrase-cipro-DNA complexes for those DNA gyrases that remove the (+) supercoiled domain in front of RNA polymerase. As a result, transcription from P~T7A1/O4~ is terminated (Fig. [3E](#Fig3){ref-type="fig"}) and the (−) supercoiling domain behind the RNA polymerase is not formed. Because P~gyrA~ is a weak promoter and transcription from P~gyrA~ should not produce significant amounts of (+) supercoils in front of RNA polymerase, gyrase-cipro-DNA complexes are not formed. In this scenario, ciprofloxacin will not be able to inhibit the expression of firefly luciferase. In contrast, the (−) DNA supercoiled domain from the divergently coupled P~T7A1/O4~ is not formed, the expression of firefly luciferase is greatly "enhanced" (Fig. [3F](#Fig3){ref-type="fig"}). Because novobiocin only inhibits DNA gyrase activities and does not form gyrase-novobiocin-DNA complexes, it should not significantly enhance or inhibit the expression of firefly luciferase in *FL1181* and *FL1182* (Fig. [4A and C](#Fig4){ref-type="fig"}). Other antibiotics, due to not affecting DNA supercoiling status *in vivo*, should not be able to enhance the expression of firefly luciferase. In contrast, they inhibited the expression of firefly luciferase and β-glactosidase in *FL1181* and *FL1182*.Figure 5A possible mechanism to explain effects of ciprofloxacin on P~gyrA~ in the presence of IPTG. In the presence of IPTG (right panel), transcription from P~T7A1/O4~ induces significant TCDS and inhibits the expression of firefly luciferase from P~gyrA~. However, in the presence of gyrase inhibitor ciprofloxacin, ciprofloxacin stabilizes gyrase-cipro-DNA complex that blocks transcription from P~T7A1/O4~. The (−) supercoils behind RNA polymerase are not formed. As a result, the expression of firefly luciferase is "enhanced."

Summary {#Sec3}
-------

Here, using a unique *in vivo* system, we demonstrated that transient and localized (−) TCDS provided by *E. coli* RNA polymerase could inhibit the P~gyrA~ at the plasmid and chromosomal levels. We also found that fluoroquinolones, such as ciprofloxacin, were able to substantially increase the expression of the firefly luciferase under the control of the P~gyrA~ in the presence of IPTG. This unique property of TCDS can be effectively used to screen and identify antimicrobial compounds targeting bacterial DNA gyrase.

Methods {#Sec4}
=======

Materials {#Sec5}
---------

Kanamycin, lysozyme, and ortho-Nitrophenyl-β-galactoside (ONPG) were purchased from Sigma-Aldrich Corporation (St. Louis, MO). Ampicillin and bovine serum albumin (BSA) were bought from Fisher Scientific (Fairlawn, NJ). Isopropyl-β-D-thiogalactopyranoside (IPTG) was obtained from Anatrace, Inc (Maumee, Ohio). All restriction enzymes, T4 DNA ligase, and T4 polynucleotide kinase were purchased from New England Biolabs (Beverly, MA). *Pfu* DNA polymerase was obtained from Stratagene, Inc. (La Jolla, CA). All synthetic oligonucleotides were purchased from Eurofins Genomics (Huntsville, AL). Plasmid and DNA fragment cleaning kits including QIAprep Spin Miniprep Kit, QIAquick Gel Extraction Kit, and QIAquick Nucleotide Removal Kit were obtained from QIAGEN, Inc. (Valencia, CA). Luciferase Assay System was bought from Promega Corporation (Madison, WI).

Plasmid DNA templates {#Sec6}
---------------------

Circular plasmid pZXD133, a derivative of pBR322, was described previously^[@CR43]^. Plasmid pZXD144 was constructed by inserting a 70 bp synthetic oligomer harboring a P~gyrA~ into the BamHI and HindIII sites of pZXD133. In this case, P~gyrA~ is divergently coupled to P~T7A1/O4~ (Fig. [1](#Fig1){ref-type="fig"}). Linear plasmid pZXD150 was described previously^[@CR38]^.

Bacterial strains {#Sec7}
-----------------

*E. coli* strains *MG1655*(*DE3*) and *VS111*(*DE3*) were described previously^[@CR22],[@CR23],[@CR43]^. *E. coli* strains *FL1181* (*MG1655*(*DE3*)*ΔlacZ attTn7*::*P*~*T7A1/O4*~*lacZ*-*P*~*gyrA*~*luc*) and *FL1182* (*VS111*(*DE3*)*ΔlacZ attTn7*::*P*~*T7A1/O4*~*lacZ*-*P*~*gyrA*~*luc*) were created by utilizing a Tn7-based site-specific recombination system^[@CR45]^ as follows. A 5.1 kb DNA fragment harboring the divergently coupled P~gyrA~ and P~T7A1/O4~ promoters controlling the *luc* and *lacZ* genes, respectively, was inserted into the *attTn*7 site of the *E. coli* chromosome^[@CR44]^ (84 min) to yield *FL1181* and *FL1182* in which the IPTG-inducible P~T7A1/O4~ controls the expression of β-galactosidase.

The expression of β-galactosidase {#Sec8}
---------------------------------

The expression level of β-galactosidase was measured as described in previous publications^[@CR38],[@CR49]^. Briefly, 100 mL of LB was inoculated with 1 mL of overnight bacterial cell culture at ratio of 1:100 until OD~600~ = \~0.2. 100 μL of bacterial cell culture was added to 900 μL of Z-buffer (60 mM Na~2~HPO~4~, 40 mM NaH~2~PO~4~, 10 mM KCl, 1 mM MgSO~4~, and 50 mM β-mercaptoethanol). Then, 60 μL of chloroform and 30 μL of 0.1% SDS were added to lyse the cells. After cell lysates were incubated at 30 °C for 5 minutes, 200 μL of ONPG (4 mg/mL) was added. After another 15 min of incubation at 30 °C, 500 μL of 1 M Na~2~CO~3~ was added to stop the reaction. After cell debris was removed by centrifugation at 13,000 rpm for 1 min, the OD~420~ and OD~550~ values were measured in a Cary 50 spectrophotometer. β-Galactosidase activities (E) were calculated using equation:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\boldsymbol{E}}=1000\times \frac{{\boldsymbol{O}}{{\boldsymbol{D}}}_{420}-1.75\times {\boldsymbol{O}}{{\boldsymbol{D}}}_{550}}{{\boldsymbol{t}}\times {\boldsymbol{v}}\times {\boldsymbol{O}}{{\boldsymbol{D}}}_{600}}$$\end{document}$$where *t* and *v*, respectively, represent reaction time and cell culture volume.

Luciferase assay {#Sec9}
----------------

The expression of the firefly luciferase in *E. coli* were monitored by using the luciferase assay as described in our previous publication^[@CR38]^.
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